Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
February 14, 2023
Genomic Profiling of Metastatic Basal cell Carcinoma Reveals Candidate Drivers of Disease and Therapeutic Targets
Ismael A Vergara, Karina Aivazian, Matteo S Carlino, et al.
The Journal of Pathology. Clinical Research
|
March 4, 2026
AI-derived prognostic biomarkers from melanoma whole slide image segmentation: an initial discovery and assessment
Emily L Clarke, Derek Magee, Julia Newton-Bishop, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
January 20, 2026
GLUT1 expression, lymphocyte distribution and CD3<sup>+</sup> T-cell metabolic subsets as predictive markers of response to immunotherapy in advanced melanoma
Elizabeth C Paver, Tuba N Gide, Zarwa Yaseen, et al.
Genome Medicine
|
May 26, 2026
Enhanced measures of neoantigenicity capture unique tumor-immune interactions across primary melanoma subtypes
Eva R Shteinman, Grace H Attrill, Nigel G Maher, et al.
NPJ Precision Oncology
|
January 22, 2026
Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma
Yizhe Mao, Tuba N Gide, Nigel G Maher, et al.
Communications Medicine
|
October 1, 2025
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma
Judith M Versluis, Huma Shehwana, Robert Elens, et al.
Cell Reports
|
June 30, 2024
Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy
Camelia Quek, Aditya Pratapa, Xinyu Bai, et al.
The New England Journal of Medicine
|
June 3, 2024
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Christian U Blank, Minke W Lucas, Richard A Scolyer, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
February 14, 2023
Genomic Profiling of Metastatic Basal cell Carcinoma Reveals Candidate Drivers of Disease and Therapeutic Targets
Ismael A Vergara, Karina Aivazian, Matteo S Carlino, et al.
The Journal of Pathology. Clinical Research
|
March 4, 2026
AI-derived prognostic biomarkers from melanoma whole slide image segmentation: an initial discovery and assessment
Emily L Clarke, Derek Magee, Julia Newton-Bishop, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
January 20, 2026
GLUT1 expression, lymphocyte distribution and CD3<sup>+</sup> T-cell metabolic subsets as predictive markers of response to immunotherapy in advanced melanoma
Elizabeth C Paver, Tuba N Gide, Zarwa Yaseen, et al.
Genome Medicine
|
May 26, 2026
Enhanced measures of neoantigenicity capture unique tumor-immune interactions across primary melanoma subtypes
Eva R Shteinman, Grace H Attrill, Nigel G Maher, et al.
NPJ Precision Oncology
|
January 22, 2026
Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma
Yizhe Mao, Tuba N Gide, Nigel G Maher, et al.
Communications Medicine
|
October 1, 2025
Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma
Judith M Versluis, Huma Shehwana, Robert Elens, et al.
Cell Reports
|
June 30, 2024
Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy
Camelia Quek, Aditya Pratapa, Xinyu Bai, et al.
The New England Journal of Medicine
|
June 3, 2024
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Christian U Blank, Minke W Lucas, Richard A Scolyer, et al.
Page
of 2